Zhang MX, Li J, Shen GP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–95. https://doi.org/10.1016/j.ejca.2015.08.006.

Article  PubMed  Google Scholar 

Yeh SA, Hwang TZ, Wang CC, et al. Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. J Radiat Res. 2021;62(3):438–47. https://doi.org/10.1093/jrr/rrab008.

Article  PubMed  PubMed Central  Google Scholar 

Li X, Kitpanit S, Lee A, et al. Toxicity profiles and survival outcomes among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated proton therapy versus intensity-modulated radiation therapy. JAMA Netw Open. 2021;4(6):e2113205. https://doi.org/10.1001/jamanetworkopen.2021.13205.

Article  PubMed  PubMed Central  Google Scholar 

Blanchard P, Lee AWM, Carmel A, et al. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): an update on 26 trials and 7080 patients. Clin Transl Radiat Oncol. 2022;32:59–68. https://doi.org/10.1016/j.ctro.2021.11.007.

Article  CAS  PubMed  Google Scholar 

Ribassin-Majed L, Marguet S, Lee AWM, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35(5):498–505. https://doi.org/10.1200/JCO.2016.67.4119.

Article  PubMed  Google Scholar 

Huang X, Chen X, Zhao C, et al. Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage ii nasopharyngeal carcinoma: a phase 2 multicenter clinical trial. Front Oncol. 2020;10:1314. https://doi.org/10.3389/fonc.2020.01314.

Article  PubMed  PubMed Central  Google Scholar 

Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II–IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol. 2021;39(7):840–59. https://doi.org/10.1200/JCO.20.03237.

Article  CAS  PubMed  Google Scholar 

Chiang CJ, Wang YW, Lee WC. Taiwan’s nationwide cancer registry system of 40 years: past, present, and future. J Formos Med Assoc. 2019;118(5):856–8. https://doi.org/10.1016/j.jfma.2019.01.012.

Article  PubMed  Google Scholar 

Au KH, Ngan RKC, Ng AWY, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018;77:16–21. https://doi.org/10.1016/j.oraloncology.2017.12.004.

Article  CAS  PubMed  Google Scholar 

Pan XB, Li L, Qu S, Chen L, Liang SX, Zhu XD. The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma. Oral Oncol. 2020;101:104520. https://doi.org/10.1016/j.oraloncology.2019.104520.

Article  PubMed  Google Scholar 

Li XY, Chen QY, Sun XS, et al. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer. 2019;110:24–31. https://doi.org/10.1016/j.ejca.2018.10.020.

Article  PubMed  Google Scholar 

Liu F, Jin T, Liu L, Xiang Z, Yan R, Yang H. The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a systematic review and meta-analysis. PLoS One. 2018;13(3):e0194733. https://doi.org/10.1371/journal.pone.0194733.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang LL, Guo R, Zhang N, et al. Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial. JAMA. 2022;328(8):728–36. https://doi.org/10.1001/jama.2022.13997.

Article  PubMed  PubMed Central  Google Scholar 

Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77. https://doi.org/10.1016/j.critrevonc.2011.04.012.

Article  PubMed  Google Scholar 

Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol. 2006;24(6):918–24. https://doi.org/10.1200/JCO.2006.10.077.

Article  CAS  PubMed  Google Scholar 

Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007. https://doi.org/10.1038/sj.ki.5002786.

Article  CAS  PubMed  Google Scholar 

Wang C, Wang F, Min X, et al. Toxicities of chemoradiotherapy and radiotherapy in nasopharyngeal carcinoma: an updated meta-analysis. J Int Med Res. 2019;47(7):2832–47. https://doi.org/10.1177/0300060519858031.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124–35. https://doi.org/10.1056/NEJMoa1905287.

Article  CAS  PubMed  Google Scholar 

Hong RL, Hsiao CF, Ting LL, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol. 2018;29(9):1972–9. https://doi.org/10.1093/annonc/mdy249.

Article  CAS  PubMed  Google Scholar 

Li WF, Chen NY, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019;145(1):295–305. https://doi.org/10.1002/ijc.32099.

Article  CAS  PubMed  Google Scholar 

Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019;119:87–96. https://doi.org/10.1016/j.ejca.2019.07.007.

Article  CAS  PubMed  Google Scholar 

Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006–02). Ann Oncol. 2018;29(3):731–6. https://doi.org/10.1093/annonc/mdx770.

Article  CAS  PubMed  Google Scholar 

Chen L, Hu CS, Chen XZ, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer. 2017;75:150–8. https://doi.org/10.1016/j.ejca.2017.01.002.

Article  CAS  PubMed  Google Scholar 

Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303–13. https://doi.org/10.1016/S0140-6736(21)01123-5.

Article  CAS  PubMed  Google Scholar 

Tang LL, Huang CL, Zhang N, et al. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022;23(4):479–90. https://doi.org/10.1016/S1470-2045(22)00058-4.

Article  PubMed  Google Scholar 

Mai H-Q, Yang J-H, Guo S-S, et al. Reduced-dose radiotherapy for pretreatment EBV DNA selected low-risk stage III nasopharyngeal carcinoma: a single-arm, phase II trial. J Clin Oncol. 2022;40(16 Suppl):6002. https://doi.org/10.1200/JCO.2022.40.16_suppl.6002.

Article  Google Scholar 

Chan ATC, Hui EP, Ngan RKC, et al. Analysis of plasma epstein-barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol. 2018;36:3091–100. https://doi.org/10.1200/JCO.2018.77.7847.

Article  CAS  Google Scholar 

Zhang Y, Chen L, Hu GQ, et al. Final ove